Neurokinin-1 receptor deletion modulates behavioural and neurochemical alterations in an animal model of depression

Behavioural Brain Research

Volumn 228, Issue 1, 2012, Pages 91-98

  Roche, M ^a   Kerr, D M ^a   Hunt, S P ^b   Kelly, J P ^a  

^a NATIONAL UNIVERSITY OF IRELAND   (Ireland)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

NK1 receptor; Noradrenaline; Olfactory bulbectomy; Open field; Serotonin; Substance P

Indexed keywords

5 HYDROXYINDOLEACETIC ACID; MONOAMINE; NEUROKININ 1 RECEPTOR; NORADRENALIN; SEROTONIN; SUBSTANCE P;

AMYGDALOID NUCLEUS; ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN REGION; CONTROLLED STUDY; DEPRESSION; DISEASE MODEL; EMOTIONALITY; EXPLORATORY BEHAVIOR; FRONTAL CORTEX; GENE; GENE DELETION; HIPPOCAMPUS; KNOCKOUT MOUSE; LOCOMOTION; MALE; MOUSE; NEUROCHEMISTRY; NEUROKININ 1 RECEPTOR GENE; NONHUMAN; OLFACTORY BULBECTOMY; OPEN FIELD TEST; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; WILD TYPE;

ANIMALS; BIOGENIC MONOAMINES; BRAIN; DEPRESSION; DISEASE MODELS, ANIMAL; EXPLORATORY BEHAVIOR; MALE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MOTOR ACTIVITY; OLFACTORY BULB; RECEPTORS, NEUROKININ-1; SUBSTANCE P;

EID: 83655164048     PISSN: 01664328     EISSN: 18727549     Source Type: Journal    
DOI: 10.1016/j.bbr.2011.11.035     Document Type: Article

References (85)

1. Nakaya Y., Kaneko T., Shigemoto R., Nakanishi S., Mizuno N. Immunohistochemical localization of substance P receptor in the central nervous system of the adult rat. J Comp Neurol 1994, 347:249-274.
2. Roberts G.W., Woodhams P.L., Polak J.M., Crow T.J. Distribution of neuropeptides in the limbic system of the rat: the amygdaloid complex. Neuroscience 1982, 7:99-131.
3. McCabe C., Cowen P.J., Harmer C.J. NK1 receptor antagonism and the neural processing of emotional information in healthy volunteers. Int J Neuropsychopharmacol 2009, 12:1261-1274.
4. Chandra P., Hafizi S., Massey-Chase R.M., Goodwin G.M., Cowen P.J., Harmer C.J. NK1 receptor antagonism and emotional processing in healthy volunteers. J Psychopharmacol 2010, 24:481-487.
5. Weiss D.W., Hirt R., Tarcic N., Berzon Y., Ben-Zur H., Breznitz S., et al. Studies in psychoneuroimmunology: psychological, immunological, and neuroendocrinological parameters in Israeli civilians during and after a period of Scud missile attacks. Behav Med 1996, 22:5-14.
6. Bondy B., Baghai T.C., Minov C., Schule C., Schwarz M.J., Zwanzger P., et al. Substance P serum levels are increased in major depression: preliminary results. Biol Psychiatry 2003, 53:538-542.
7. Geracioti T.D., Carpenter L.L., Owens M.J., Baker D.G., Ekhator N.N., Horn P.S., et al. Elevated cerebrospinal fluid substance p concentrations in posttraumatic stress disorder and major depression. Am J Psychiatry 2006, 163:637-643.
8. Sergeyev V., Fetissov S., Mathe A.A., Jimenez P.A., Bartfai T., Mortas P., et al. Neuropeptide expression in rats exposed to chronic mild stresses. Psychopharmacology (Berl) 2005, 178:115-124.
9. Duric V., McCarson K.E. Hippocampal neurokinin-1 receptor and brain-derived neurotrophic factor gene expression is decreased in rat models of pain and stress. Neuroscience 2005, 133:999-1006.
10. Kramer M.S., Cutler N., Feighner J., Shrivastava R., Carman J., Sramek J.J., et al. Distinct mechanism for antidepressant activity by blockade of central substance P receptors. Science 1998, 281:1640-1645.
11. Husum H., Vasquez P.A., Mathe A.A. Changed concentrations of tachykinins and neuropeptide Y in brain of a rat model of depression: lithium treatment normalizes tachykinins. Neuropsychopharmacology 2001, 24:183-191.
12. Malkesman O., Braw Y., Weller A. Assessment of antidepressant and anxiolytic properties of NK1 antagonists and substance P in Wistar Kyoto rats. Physiol Behav 2007, 90:619-625.
13. Ebner K., Rupniak N.M., Saria A., Singewald N. Substance P in the medial amygdala: emotional stress-sensitive release and modulation of anxiety-related behavior in rats. Proc Natl Acad Sci U S A 2004, 101:4280-4285.
14. Rupniak N.M., Carlson E.C., Harrison T., Oates B., Seward E., Owen S., et al. Pharmacological blockade or genetic deletion of substance P (NK(1)) receptors attenuates neonatal vocalisation in guinea-pigs and mice. Neuropharmacology 2000, 39:1413-1421.
15. Rupniak N.M., Carlson E.J., Webb J.K., Harrison T., Porsolt R.D., Roux S., et al. Comparison of the phenotype of NK1R-/- mice with pharmacological blockade of the substance P (NK1) receptor in assays for antidepressant and anxiolytic drugs. Behav Pharmacol 2001, 12:497-508.
16. Bilkei-Gorzo A., Racz I., Michel K., Zimmer A. Diminished anxiety- and depression-related behaviors in mice with selective deletion of the Tac1 gene. J Neurosci 2002, 22:10046-10052.
17. Ebner K., Singewald N. The role of substance P in stress and anxiety responses. Amino Acids 2006, 31:251-272.
18. Yan T.C., Hunt S.P., Stanford S.C. Behavioural and neurochemical abnormalities in mice lacking functional tachykinin-1 (NK1) receptors: a model of attention deficit hyperactivity disorder. Neuropharmacology 2009, 57:627-635.
19. Ma Q.P., Bleasdale C. Modulation of brain stem monoamines and gamma-aminobutyric acid by NK1 receptors in rats. Neuroreport 2002, 13:1809-1812.
20. Leger L., Gay N., Cespuglio R. Neurokinin NK1- and NK3-immunoreactive neurons in serotonergic cell groups in the rat brain. Neurosci Lett 2002, 323:146-150.
21. Commons K.G., Valentino R.J. Cellular basis for the effects of substance P in the periaqueductal gray and dorsal raphe nucleus. J Comp Neurol 2002, 447:82-97.
22. Valentino R.J., Bey V., Pernar L., Commons K.G. Substance P Acts through local circuits within the rat dorsal raphe nucleus to alter serotonergic neuronal activity. J Neurosci 2003, 23:7155-7159.
23. Guiard B.P., Guilloux J.P., Reperant C., Hunt S.P., Toth M., Gardier A.M. Substance P neurokinin 1 receptor activation within the dorsal raphe nucleus controls serotonin release in the mouse frontal cortex. Mol Pharmacol 2007, 72:1411-1418.
24. Santarelli L., Gobbi G., Debs P.C., Sibille E.T., Blier P., Hen R., et al. Genetic and pharmacological disruption of neurokinin 1 receptor function decreases anxiety-related behaviors and increases serotonergic function. Proc Natl Acad Sci U S A 2001, 98:1912-1917.
25. Conley R.K., Cumberbatch M.J., Mason G.S., Williamson D.J., Harrison T., Locker K., et al. Substance P (neurokinin 1) receptor antagonists enhance dorsal raphe neuronal activity. J Neurosci 2002, 22:7730-7736.
26. Froger N., Gardier A.M., Moratalla R., Alberti I., Lena I., Boni C., et al. 5-Hydroxytryptamine (5-HT)1A autoreceptor adaptive changes in substance P (neurokinin 1) receptor knock-out mice mimic antidepressant-induced desensitization. J Neurosci 2001, 21:8188-8197.
27. Millan M.J., Lejeune F., De Nanteuil G., Gobert A. Selective blockade of neurokinin (NK)(1) receptors facilitates the activity of adrenergic pathways projecting to frontal cortex and dorsal hippocampus in rats. J Neurochem 2001, 76:1949-1954.
28. Zocchi A., Varnier G., Arban R., Griffante C., Zanetti L., Bettelini L., et al. Effects of antidepressant drugs and GR 205171, an neurokinin-1 (NK1) receptor antagonist, on the response in the forced swim test and on monoamine extracellular levels in the frontal cortex of the mouse. Neurosci Lett 2003, 345:73-76.
29. Guiard B.P., Przybylski C., Guilloux J.P., Seif I., Froger N., De Felipe C., et al. Blockade of substance P (neurokinin 1) receptors enhances extracellular serotonin when combined with a selective serotonin reuptake inhibitor: an in vivo microdialysis study in mice. J Neurochem 2004, 89:54-63.
30. Saffroy M., Beaujouan J.C., Petitet F., Torrens Y., Glowinski J. Differential localization of 3H-[Pro9]SP binding sites in the guinea pig and rat brain. Brain Res 1994, 633:317-325.
31. Gobbi G., Blier P. Effect of neurokinin-1 receptor antagonists on serotoninergic, noradrenergic and hippocampal neurons: comparison with antidepressant drugs. Peptides 2005, 26:1383-1393.
32. Maubach K.A., Martin K., Chicchi G., Harrison T., Wheeldon A., Swain C.J., et al. Chronic substance P (NK1) receptor antagonist and conventional antidepressant treatment increases burst firing of monoamine neurones in the locus coeruleus. Neuroscience 2002, 109:609-617.
33. Ebner K., Singewald N. Stress-induced release of substance P in the locus coeruleus modulates cortical noradrenaline release. Naunyn Schmiedebergs Arch Pharmacol 2007, 376:73-82.
34. Herpfer I., Hunt S.P., Stanford S.C. A comparison of neurokinin 1 receptor knock-out (NK1-/-) and wildtype mice: exploratory behaviour and extracellular noradrenaline concentration in the cerebral cortex of anaesthetised subjects. Neuropharmacology 2005, 48:706-719.
35. Fisher A.S., Stewart R.J., Yan T., Hunt S.P., Stanford S.C. Disruption of noradrenergic transmission and the behavioural response to a novel environment in NK1R-/- mice. Eur J Neurosci 2007, 25:1195-1204.
36. Song C., Leonard B.E. The olfactory bulbectomised rat as a model of depression. Neurosci Biobehav Rev 2005, 29:627-647.
37. Kelly J.P., Wrynn A.S., Leonard B.E. The olfactory bulbectomized rat as a model of depression: an update. Pharmacol Ther 1997, 74:299-316.
38. De Felipe C., Herrero J.F., O'Brien J.A., Palmer J.A., Doyle C.A., Smith A.J., et al. Altered nociception, analgesia and aggression in mice lacking the receptor for substance P. Nature 1998, 392:394-397.
39. Bradford M.M. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 1976, 72:248-254.
40. Otmakhova N.A., Gurevich E.V., Katkov Y.A., Nesterova I.V., Bobkova N.V. Dissociation of multiple behavioral effects between olfactory bulbectomized C57Bl/6J and DBA/2J mice. Physiol Behav 1992, 52:441-448.
41. Gurevich E.V., Aleksandrova I.A., Otmakhova N.A., Katkov Y.A., Nesterova I.V., Bobkova N.V. Effects of bulbectomy and subsequent antidepressant treatment on brain 5-HT2 and 5-HT1A receptors in mice. Pharmacol Biochem Behav 1993, 45:65-70.
42. Nesterova I.V., Gurevich E.V., Nesterov V.I., Otmakhova N.A., Bobkova N.V. Bulbectomy-induced loss of raphe neurons is counteracted by antidepressant treatment. Prog Neuropsychopharmacol Biol Psychiatry 1997, 21:127-140.
43. Jarosik J., Legutko B., Unsicker K., von Bohlen Und Halbach O. Antidepressant-mediated reversal of abnormal behavior and neurodegeneration in mice following olfactory bulbectomy. Exp Neurol 2007, 204:20-28.
44. Grecksch G., Zhou D., Franke C., Schroder U., Sabel B., Becker A., et al. Influence of olfactory bulbectomy and subsequent imipramine treatment on 5-hydroxytryptaminergic presynapses in the rat frontal cortex: behavioural correlates. Br J Pharmacol 1997, 122:1725-1731.
45. Roche M., Shanahan E., Harkin A., Kelly J.P. Trans-species assessment of antidepressant activity in a rodent model of depression. Pharmacol Rep 2008, 60:404-408.
46. Roche M., Harkin A., Kelly J.P. Chronic fluoxetine treatment attenuates stressor-induced changes in temperature, heart rate, and neuronal activation in the olfactory bulbectomized rat. Neuropsychopharmacology 2007, 32:1312-1320.
47. Zueger M., Urani A., Chourbaji S., Zacher C., Roche M., Harkin A., et al. Olfactory bulbectomy in mice induces alterations in exploratory behavior. Neurosci Lett 2005, 374:142-146.
48. Butler R.K., Nilsson-Todd L., Cleren C., Lena I., Garcia R., Finn D.P. Molecular and electrophysiological changes in the prefrontal cortex-amygdala-dorsal periaqueductal grey pathway during persistent pain state and fear-conditioned analgesia. Physiol Behav 2011, 104(5):1075-1081.
49. Butler R.K., Rea K., Lang Y., Gavin A.M., Finn D.P. Endocannabinoid-mediated enhancement of fear-conditioned analgesia in rats: opioid receptor dependency and molecular correlates. Pain 2008, 140:491-500.
50. Castro A.R., Pinto M., Lima D., Tavares I. Imbalance between the expression of NK1 and GABAB receptors in nociceptive spinal neurons during secondary hyperalgesia: a c-Fos study in the monoarthritic rat. Neuroscience 2005, 132:905-916.
51. Piggins H.D., Samuels R.E., Coogan A.N., Cutler D.J. Distribution of substance P and neurokinin-1 receptor immunoreactivity in the suprachiasmatic nuclei and intergeniculate leaflet of hamster, mouse, and rat. J Comp Neurol 2001, 438:50-65.
52. Roche M., Johnston P., Mhuircheartaigh O.N., Olango W.M., Mackie K., Finn D.P. Effects of intra-basolateral amygdala administration of rimonabant on nociceptive behaviour and neuronal activity in the presence or absence of contextual fear. Eur J Pain 2010, 14:487-495.
53. Smith K.L., Roche M., Jessop D.S., Finn D.P. The effects of synthetic and endogenous imidazoline binding site ligands on neuronal activity in discrete brain regions of naive and restraint-stressed rats. Eur Neuropsychopharmacol 2009, 19:371-380.
54. Burke N.N., Hayes E., Calpin P., Kerr D.M., Moriarty O., Finn D.P., et al. Enhanced nociceptive responding in two rat models of depression is associated with alterations in monoamine levels in discrete brain regions. Neuroscience 2011, 171:1300-1313.
55. Roche M., O'Connor E., Diskin C., Finn D.P. The effect of CB(1) receptor antagonism in the right basolateral amygdala on conditioned fear and associated analgesia in rats. Eur J Neurosci 2007, 26:2643-2653.
56. Rupniak N.M. New insights into the antidepressant actions of substance P (NK1 receptor) antagonists. Can J Physiol Pharmacol 2002, 80:489-494.
57. McLean S. Do substance P and the NK1 receptor have a role in depression and anxiety?. Curr Pharm Des 2005, 11:1529-1547.
58. Boyce S., Smith D., Carlson E., Hewson L., Rigby M., O'Donnell R., et al. Intra-amygdala injection of the substance P [NK(1) receptor] antagonist L-760735 inhibits neonatal vocalisations in guinea-pigs. Neuropharmacology 2001, 41:130-137.
59. Smith D.W., Hewson L., Fuller P., Williams A.R., Wheeldon A., Rupniak N.M. The substance P antagonist L-760,735 inhibits stress-induced NK(1) receptor internalisation in the basolateral amygdala. Brain Res 1999, 848:90-95.
60. Shaikh M.B., Steinberg A., Siegel A. Evidence that substance P is utilized in medial amygdaloid facilitation of defensive rage behavior in the cat. Brain Res 1993, 625:283-294.
61. Han Y., Shaikh M.B., Siegel A. Medial amygdaloid suppression of predatory attack behavior in the cat: I. Role of a substance P pathway from the medial amygdala to the medial hypothalamus. Brain Res 1996, 716:59-71.
62. Jancsar S.M., Leonard B.E. Changes in neurotransmitter metabolism following olfactory bulbectomy in the rat. Prog Neuropsychopharmacol Biol Psychiatry 1984, 8:263-269.
63. Shibata S., Watanabe S. Facilitatory effect of olfactory bulbectomy on 2-deoxyglucose uptake in rat amygdala slices. Brain Res 1994, 665:147-150.
64. McNish K.A., Davis M. Olfactory bulbectomy enhances sensitization of the acoustic startle reflex produced by acute or repeated stress. Behav Neurosci 1997, 111:80-91.
65. Primeaux S.D., Holmes P.V. Role of aversively motivated behavior in the olfactory bulbectomy syndrome. Physiol Behav 1999, 67:41-47.
66. Stock H.S., Hand G.A., Ford K., Wilson M.A. Changes in defensive behaviors following olfactory bulbectomy in male and female rats. Brain Res 2001, 903:242-246.
67. Nesterova I.V., Bobkova N.V., Medvinskaya N.I., Samokhin A.N., Aleksandrova I.Y. Morphofunctional state of neurons in the temporal cortex and hippocampus in relation to the level of spatial memory in rats after ablation of the olfactory bulbs. Neurosci Behav Physiol 2008, 38:349-353.
68. Ostrovskaya R.U., Gruden M.A., Bobkova N.A., Sewell R.D., Gudasheva T.A., Samokhin A.N., et al. The nootropic and neuroprotective proline-containing dipeptide noopept restores spatial memory and increases immunoreactivity to amyloid in an Alzheimer's disease model. J Psychopharmacol 2007, 21:611-619.
69. Hozumi S., Nakagawasai O., Tan-No K., Niijima F., Yamadera F., Murata A., et al. Characteristics of changes in cholinergic function and impairment of learning and memory-related behavior induced by olfactory bulbectomy. Behav Brain Res 2003, 138:9-15.
70. Kameyama T., Ukai M., Shinkai N. Ameliorative effects of tachykinins on scopolamine-induced impairment of spontaneous alternation performance in mice. Methods Find Exp Clin Pharmacol 1998, 20:555-560.
71. Hasenohrl R.U., Souza-Silva M.A., Nikolaus S., Tomaz C., Brandao M.L., Schwarting R.K., et al. Substance P and its role in neural mechanisms governing learning, anxiety and functional recovery. Neuropeptides 2000, 34:272-280.
72. Acsady L., Katona I., Gulyas A.I., Shigemoto R., Freund T.F. Immunostaining for substance P receptor labels GABAergic cells with distinct termination patterns in the hippocampus. J Comp Neurol 1997, 378:320-336.
73. Ogier R., Wrobel L.J., Raggenbass M. Action of tachykinins in the hippocampus: facilitation of inhibitory drive to GABAergic interneurons. Neuroscience 2008, 156:527-536.
74. Ogier R., Raggenbass M. Action of tachykinins in the rat hippocampus: modulation of inhibitory synaptic transmission. Eur J Neurosci 2003, 17:2639-2647.
75. Yan T.C., McQuillin A., Thapar A., Asherson P., Hunt S.P., Stanford S.C., et al. NK1 (TACR1) receptor gene 'knockout' mouse phenotype predicts genetic association with ADHD. J Psychopharmacol 2010, 24:27-38.
76. McCutcheon J.E., Fisher A.S., Guzdar E., Wood S.A., Lightman S.L., Hunt S.P. Genetic background influences the behavioural and molecular consequences of neurokinin-1 receptor knockout. Eur J Neurosci 2008, 27:683-690.
77. File S.E. Anxiolytic action of a neurokinin1 receptor antagonist in the social interaction test. Pharmacol Biochem Behav 1997, 58:747-752.
78. Brocco M., Dekeyne A., Mannoury la Cour C., Touzard M., Girardon S., Veiga S., et al. Cellular and behavioural profile of the novel, selective neurokinin1 receptor antagonist, vestipitant: a comparison to other agents. Eur Neuropsychopharmacol 2008, 18:729-750.
79. Frisch P., Bilkei-Gorzo A., Racz I., Zimmer A. Modulation of the CRH system by substance P/NKA in an animal model of depression. Behav Brain Res 2010, 213:103-108.
80. Hellweg R., Zueger M., Fink K., Hortnagl H., Gass P. Olfactory bulbectomy in mice leads to increased BDNF levels and decreased serotonin turnover in depression-related brain areas. Neurobiol Dis 2007, 25:1-7.
81. Lumia A.R., Teicher M.H., Salchli F., Ayers E., Possidente B. Olfactory bulbectomy as a model for agitated hyposerotonergic depression. Brain Res 1992, 587:181-185.
82. van der Stelt H.M., Breuer M.E., Olivier B., Westenberg H.G. Permanent deficits in serotonergic functioning of olfactory bulbectomized rats: an in vivo microdialysis study. Biol Psychiatry 2005, 57:1061-1067.
83. Redmond A.M., Kelly J.P., Leonard B.E. Behavioural and neurochemical effects of dizocilpine in the olfactory bulbectomized rat model of depression. Pharmacol Biochem Behav 1997, 58:355-359.
84. Connor T.J., Song C., Leonard B.E., Anisman H., Merali Z. Stressor-induced alterations in serotonergic activity in an animal model of depression. Neuroreport 1999, 10:523-528.
85. Saitoh A., Yamaguchi K., Tatsumi Y., Murasawa H., Nakatani A., Hirose N., et al. Effects of milnacipran and fluvoxamine on hyperemotional behaviors and the loss of tryptophan hydroxylase-positive cells in olfactory bulbectomized rats. Psychopharmacology (Berl) 2007, 191:857-865.